|Bid||67.18 x 100|
|Ask||67.19 x 100|
|Day's Range||66.95 - 67.40|
|52 Week Range||52.59 - 72.58|
|PE Ratio (TTM)||52.04|
|Earnings Date||Apr 26, 2018|
|Forward Dividend & Yield||0.64 (0.97%)|
|1y Target Est||75.71|
Positive tidings on regulatory front, expanding Hospital-Products portfolio, strategic collaborations and strong presence in the international markets are key positives for Baxter's (BAX) Q1 results.
Favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with its price performance
The dividend will be payable on May 15, 2018, to shareholders of record on April 13, 2018. Abbott Laboratories is part of the S&P 500 Dividend Aristocrats, which are the companies that have paid out consistently increasing dividends to shareholders for at least 25 consecutive years. As of April 6, 2018, ABT stock has a dividend yield of 1.9%.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BAX. Over the last one-month, outflows of investor capital in ETFs holding BAX totaled $16.11 billion.
Baxter International Inc. , will host a conference call to discuss its first quarter 2018 financial results on Thursday, April 26, 2018, at 7:30 a.m. Central Daylight Time.
Baxter International Inc. will host a webcast of its Annual Meeting of Stockholders on Tuesday, May 8, 2018 at 9:00 a.m. Central Time.
Moody's Investors Service, ("Moody's") upgraded Baxter International Inc.'s ("Baxter") senior unsecured rating to Baa1 from Baa2. Moody's also affirmed the company's Prime-2 commercial ...
Who Is Watching Baxter International in March 2018? For fiscal 2018, Baxter International (BAX) changed its reporting structure from the previous year. The company has two segments—Hospital Products and Renal—with a range of one to six global businesses.
Who Is Watching Baxter International in March 2018? For fiscal 2017, Baxter International (BAX) reported revenues of ~$10.6 billion, which represents 4.0% YoY growth on a reported basis and a 5.0% rise on an operational basis. The company has projected its annual revenues for 2018 to be 6.0%–7.0% higher year-over-year (or YoY) on a reported basis.
Who Is Watching Baxter International in March 2018? Baxter International’s (BAX) top-line performance in 4Q17 was mainly driven by increased demand for the company’s Fluid Systems’ products. Baxter International also witnessed rising demand for its cytotoxic contract manufacturing services.
In December 2017, Baxter International Inc (NYSE:BAX) released its most recent earnings update. Generally, analysts seem highly optimistic, with profits predicted to ramp up by an impressive 90.05% next year,Read More...
Baxter International (BAX) announced the completion of its acquisition of Recothrom and Preveleak assets from Mallinckrodt Pharmaceuticals (MNK) for a total consideration of $185.0 million. This transaction includes $153.0 million in upfront payments and the rest in future milestone-based payments. Additionally, Baxter International has assumed Preveleak’s associated expenses and the contingent liabilities. Preveleak’s manufacturing operations are also included in the deal.